Immunohistochemistry can be beneficial when it comes to making the differential diagnosis, as BCC show positivity for Ber-EP4, BCL2 (67%–100%), SMA (78%–95%), CD117 (93%) and some neuroendocrine, such as CD56 (77%) and chromogranin A (27%–72%), while basaloid SCC is often negative for these markers [5, 7, 8, 11–13]. This evidence concerns the gene SMN1 and skin basal cell carcinoma.